Bg pattern

COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Prospect:information for the user

COLIROFTA ATROPINA 10 mg/ml eye drops in solution

Read the entire prospectus carefully before starting to use this medication, as it contains important information for you.

  • Keep this prospectus, as you may need to read it again.
  • If you have any doubts, consult your doctor or pharmacist.
  • This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
  • If you experience adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospectus. See section 4.

Contents of the prospectus

  1. What COLIROFTA ATROPINA 10 mg/ml is and what it is used for
  2. What you need to know before starting to use COLIROFTA ATROPINA 10 mg/ml
  3. How to use COLIROFTA ATROPINA 10 mg/ml
  4. Possible adverse effects

5 Conservation of COLIROFTA ATROPINA 10 mg/ml

  1. Contents of the package and additional information

1. What COLIROFTA ATROPINA 10 mg/ml is and what it is used for

It is an eye drop that contains atropine, an anticholinergic agent (blocks some of the acetylcholine receptors, a neurotransmitter) that, when administered in the eyes, produces mydriasis (pupil dilation) and cycloplegia (paralysis of the muscle that produces accommodation).

Colirofta Atropina 10 mg/ml is indicated:

  • In eye exams, to dilate the pupil and prevent eye focusing.
  • For the treatment of acute inflammatory eye conditions in the anterior part of the eye, such as inflammation of the colored part of the eye (iritis) and of the iris and ciliary body (iridocyclitis).
Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before starting to use COLIROFTA ATROPINA 10 mg/ml

Do not use COLIROFTA ATROPINA 10 mg/ml

  • If you are allergic to atropine or any of the other components of this medication (listed in section 6).
  • If you have or think you may have primary glaucoma or a predisposition to narrow-angle glaucoma (increased pressure in the eye).
  • Children with Down syndrome, spastic paralysis (a type of cerebral palsy), or brain injury.
  • Children under 3 years of age.
  • Children who have had a previous severe reaction to the active ingredient of this medication, atropine.

(See section 2, "Pregnancy, breastfeeding, and fertility").

Warnings and precautions

Consult your doctor or pharmacist before starting to use Colirofta Atropina 10 mg/ml.

  • Use this medication only in your eye(s).
  • After application, keep your eyes closed while gently pressing the tear duct with your finger for at least 1 minute. See section 3 "How to use...".
  • The use of this medication may cause:
  • Increased pressure in the eye and glaucoma, especially in elderly patients. Eye pressure should be monitored frequently and also before starting treatment, under medical supervision.
  • Changes in behavior (such as delirium), especially in children and elderly patients, although these reactions can occur at any age.
  • Sensitivity to light. Protect your eyes from intense light (sunglasses).
  • Blurred vision that can last up to 2 weeks.
  • If you have a fever or are exposed to high temperatures, especially in children, caution is required, as this medication can increase body temperature.
  • Great caution is needed in patients with heart disease, arrhythmias, or recent myocardial infarction, as tachycardias (increased heart rate) may occur. It is recommended to reduce the dose.

It may cause an increase in blood pressure.

  • Cautious use is required in patients with:
  • significant kidney disease
  • chronic pulmonary diseases
  • or symptoms of the lower urinary tract, such as prostate hyperplasia.
  • Do not use this medication at the same time as treatment with MAOI medications (usually antidepressants) (see "Other medications...").

Children

  • This medication will be used with caution in children over 3 years of age.
  • Premature children and those with low birth weight or patients with Down syndrome, spastic paralysis, brain injury, or children with fair skin and blue eyes are especially sensitive to the adverse effects of this medication. Consult your doctor to inform you about the serious adverse reactions that may occur with the use of this medication.
  • Avoid children putting this medication in their mouth or cheeks. Wash your hands and the children's cheeks or hands immediately after administration.

Other medications and COLIROFTA ATROPINA 10 mg/ml

Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.

Especially, tell your doctor if you are using:

Medications that share properties with the active ingredient of the medication, such as:

  • Amantadine (antiviral medication and for Parkinson's disease, which stimulates the central nervous system)
  • For obstructive pulmonary diseases, such as: tiotropium, glycopyrronium, or revefenacin
  • Scopolamine (used previously to anesthesia)
  • Certain antihistamines (medications used to treat allergies)
  • Antipsychotics (used to treat psychiatric conditions)
  • Tricyclic antidepressants (medications used to treat depression).

Other medications:

  • Donepezil (used in Alzheimer's disease)
  • Heart stimulants
  • MAOI medications (generally used to treat depression).

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

This medication is not recommended during pregnancy or breastfeeding.

Driving and using machines

The influence of this medication on the ability to drive and use machines is significant.

This medication can cause blurred vision and sensitivity to light for a prolonged period, which can last several days. Do not drive or use machines or tools until your vision is clear.

COLIROFTA ATROPINA 10 mg/ml containsmethylparahydroxybenzoate (E-218) and propylparahydroxybenzoate (E-216) and phosphates

This medication may cause allergic reactions (possibly delayed) because it contains methylparahydroxybenzoate (E-218) and propylparahydroxybenzoate (E-216).

This medication contains 6 mg of phosphates per ml.

If you have severe corneal damage (the transparent layer of the front of the eye), treatment with phosphates, in very rare cases, can cause blurred vision due to calcium accumulation.

3. How to use COLIROFTA ATROPINA 10 mg/ml

Follow the administration instructions of this medication indicated by your doctor or pharmacist exactly. If in doubt, consult your doctor or pharmacist again.

The recommended dose is:

Adults

When a sustained effect is intended, three daily applications of 2 drops are usually performed.

For refraction examination, 1 or 2 drops will be instilled in each eye twice a day, 1 to 3 days before the examination.

Use in children

Children (over 3 years of age)

Due to the risk of producing severe systemic adverse effects, this medication is contraindicated in children under 3 years of age and is recommended to be used with caution in children over 3 years. The lowest effective dose possible is recommended to reduce the risk of systemic adverse effects (see "Warnings and precautions").

When a sustained effect is intended, three daily applications of 1 drop are usually performed.

For refraction examination, 1 or 2 drops will be instilled in each eye twice a day, 1 to 3 days before the examination.

Remember to apply your medication according to your doctor's instructions.

Use in elderly patients

Use with caution in elderly patients, as they may have a higher risk of undiagnosed glaucoma and behavioral disorders.

Your doctor will indicate the duration of your treatment with Colirofta Atropina 10 mg/ml. Do not stop treatment before, unless your doctor indicates it.

Recommendations for use:

Ophthalmic route (in the eyes).

Hand holding an eye drop applicator, tilting the head back and opening the lower eyelid

1 2 3

  1. Wash your hands.
  2. Take the bottle.
  3. After opening the bottle for the first time, remove the plastic ring from the seal if it is loose.
  4. Hold the bottle, upside down, between your fingers.
  5. Tilt your head back. Gently separate the eyelid from the eye with your finger until a pocket forms between the eyelid and your eye, where the drop should fall (figure 1).
  6. Bring the tip of the bottle close to the eye. You may find it helpful to use a mirror.
  7. Do not touch the eye or eyelid, or nearby areas, with the dropper. The drops may become contaminated.
  8. Gently squeeze the base of the bottle with your index finger to release one drop at a time (figure 2).
  9. After using this eye drop, release the lower eyelid, close your eye, and gently press the edge of the eye, next to the nose, for at least 1 minute. This helps prevent the medication from entering the rest of the body (figure 3).
  10. If you are applying drops in both eyes, repeat all the previous steps with the other eye.
  11. Close the bottle tightly immediately after use.
  12. Remember to wash your hands after administering this medication.

If a drop falls outside the eye, try again.

If you are using other ophthalmic medications, wait at least 5 minutes between the administration of this eye drop and other ophthalmic medications. Ophthalmic ointments should be administered last.

If you use more COLIROFTA ATROPINA 10 mg/ml than you should

You can eliminate it by washing your eyes with warm water. Do not apply more drops until it is time for your next dose. The symptoms of overdose may include redness and dryness of the skin (in children, it may present as a rash), blurred vision, rapid and irregular pulse, fever, abdominal swelling in children, convulsions, hallucinations, loss of coordination, and rapid progressive respiratory depression.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service. Phone: 91 562 04 20, indicating the medication and the amount used.

If you forget to use COLIROFTA ATROPINA 10 mg/ml

Do not apply a double dose to make up for forgotten doses.

Apply a single dose as soon as you remember and continue with the next dose that was scheduled. However, if it is almost time for the next dose, do not apply the forgotten dose and continue with the next dose of your regular regimen.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible adverse effects

Like all medications, this medication can cause adverse effects, although not all people experience them.

The following reactions have been reported during post-marketing experience:

Frequency not known(cannot be estimated from the available data):

  • Ocular effects:blurred vision, increased pupil size (prolonged effect of the medication), eyelid swelling, sensitivity to light.
  • General effects: allergy, increased or decreased heart rate, headache, dizziness, hallucination, confusion, disorientation, intestinal obstruction, abdominal swelling, vomiting, redness or inflammation of the skin, rash, fever.

Other adverse effects in children

Children are more likely to exhibit the general adverse effects described above, especially in premature children and those with low birth weight or patients with Down syndrome, spastic paralysis, or brain injury (see section 2, "Do not use...").

Reporting adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

5. Conservation of COLIROFTA ATROPINA 10 mg/ml

Keep this medication out of the sight and reach of children.

Store below 25°C.

Do not use this medication after the expiration date that appears on the bottle and on the box after EXP. The expiration date is the last day of the month indicated.

To avoid infections, the bottle must be discarded 4 weeks after it was first opened.

Write the opening date of the bottle in the box provided for this purpose.

Medications should not be thrown away in drains or trash. Deposit the packaging and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.

6. Contents of the package and additional information

Composition of COLIROFTA ATROPINA 10 mg/ml

  • The active ingredient is atropine. One ml of eye drop solution contains 10 mg of atropine (as sulfate) (1%).
  • The other components are: methylparahydroxybenzoate (E-218), propylparahydroxybenzoate (E-216), sodium chloride, sodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, and purified water.

Appearance of the product and contents of the package

Colirofta Atropina 10 mg/ml is an eye drop solution; it is a clear and colorless liquid that comes in a 10 ml dropper bottle (plastic bottle) with a sealed cap.

Marketing authorization holder and manufacturer

Marketing authorization holder

Alcon Healthcare S.A.

World Trade Center Almeda Park

Plaça de la Pau s/n, Edificio 6, planta 3

08940 - Cornellà de Llobregat (Barcelona)

Spain

Manufacturer

Siegfried El Masnou, S.A.

C/ Camil Fabra, 58

08320 El Masnou – Barcelona

Spain

or

Alcon Laboratories Belgium

Lichterveld 3

2870 Puurs-Sint-Amands

Belgium

Date of the last revision of this prospectus:May 2020

Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es

Online doctors for COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION

Discuss questions about COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION?
COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION?
The active ingredient in COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION is atropine. This information helps identify medicines with the same composition but different brand names.
How much does COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION cost in pharmacies?
The average pharmacy price for COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION is around 5.39 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION?
COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION is manufactured by Alcon Healthcare S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION?
Other medicines with the same active substance (atropine) include COLIROFTA ATROPINE 5 mg/ml EYE DROPS SOLUTION, COLIROFTA CICLOPLÉJICO 10 mg/ml EYE DROPS SOLUTION, COLIROFTA TROPICAMIDE 10 mg/ml EYE DROPS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media